GW Pharma’s Cannabidiol For Seizures One Step Closer To European Approval

The CHMP has issued a positive opinion for Epidyolex for two rare conditions. The cannabidiol product was approved in the US in 2018.

Cannabis_Leaf
Green light for first centralized approval of plant-based cannabis medicine in EU • Source: Shutterstock

GW Pharmaceuticals PLC’s orphan drug Epidyolex (cannabidiol) has been granted a positive opinion by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).

The product, an oral solution, is recommended to be used alongside clobazam to treat seizures associated with the rare conditions...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip